Page last updated: 2024-10-31

metoclopramide and ER-Negative PR-Negative HER2-Negative Breast Cancer

metoclopramide has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.

Research Excerpts

ExcerptRelevanceReference
"Metoclopramide is a good and cost-effective therapeutic option for chemotherapy-induced nausea and vomiting."1.62The anti-cancer effect of metoclopramide on triple-negative breast cancer cells. ( Chen, Y; Fan, R; Ji, X; Ji, Y; Liu, Y; Lu, P; Qin, S; Zhang, M; Zhao, J, 2021)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chen, Y1
Zhang, M1
Ji, X1
Zhao, J1
Qin, S1
Ji, Y1
Fan, R1
Liu, Y1
Lu, P1

Other Studies

1 other study available for metoclopramide and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
The anti-cancer effect of metoclopramide on triple-negative breast cancer cells.
    Die Pharmazie, 2021, 04-01, Volume: 76, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dopamine D2 Receptor Antagon

2021